{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T16:07:41Z","timestamp":1793549261074,"version":"4.5.0"},"reference-count":145,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases. We propose studies to advance IL-23 biology and unravel differences in response to anti\u2013IL-23 therapy. Experimental evidence generated from these investigations could establish a novel molecular ontology centered around IL-23\u2013driven diseases, improve upon current approaches to treating IMIDs with IL-23 inhibition, and ultimately facilitate optimal identification of patients and, thereby, outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1331217","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T04:20:19Z","timestamp":1713154819000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":155,"title":["IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"James G.","family":"Krueger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Kuchroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Merle","family":"Elloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Fourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fakharzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Sherlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Cua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2018.12.002","article-title":"IL-23 in inflammatory bowel diseases and colon cancer","volume":"45","author":"Neurath","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-018-0126-0","article-title":"Two distinct colonic CD14+ subsets characterized by single-cell RNA profiling in Crohn's disease","volume":"12","author":"Chapuy","year":"2019","journal-title":"Mucosal Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.04.021","article-title":"Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets","volume":"148","author":"Kim","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-309014","article-title":"Tissue-infiltrating neutrophils represent the main source of IL-23 in the colon of patients with IBD","volume":"65","author":"Kvedaraite","year":"2016","journal-title":"Gut"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1698","article-title":"The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo","volume":"10","author":"McGeachy","year":"2009","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax6624","article-title":"MAIT cells are imprinted by the microbiota in early life and promote tissue repair","volume":"366","author":"Constantinides","year":"2019","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nri2800","article-title":"Innate IL-17-producing cells: the sentinels of the immune system","volume":"10","author":"Cua","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.immuni.2022.08.007","article-title":"Induction of a colitogenic phenotype in Th1-like cells depends on interleukin-23 receptor signaling","volume":"55","author":"Pawlak","year":"2022","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature09447","article-title":"Generation of pathogenic TH17 cells in the absence of TGF-\u03b2 signalling","volume":"467","author":"Ghoreschi","year":"2010","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.05.003","article-title":"Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis","volume":"32","author":"Durant","year":"2010","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101712","article-title":"IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease","volume":"208","author":"Geremia","year":"2011","journal-title":"J Exp Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy099","article-title":"Selective IL-23 inhibition by risankizumab modulates the molecular profile in the colon and ileum of patients with active Crohn's disease: results from a randomised phase II biopsy sub-study","volume":"12","author":"Visvanathan","year":"2018","journal-title":"J Crohn's colitis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.42010","article-title":"Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20568","article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2","volume":"185","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20595","article-title":"Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up","volume":"185","author":"Papp","year":"2021","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00474-5","article-title":"Long-term efficacy and safety of risankizumab in patients with active psoriatic arthritis: results from a 76-week phase 2 randomized trial","volume":"9","author":"Mease","year":"2022","journal-title":"Rheumatol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001457","article-title":"Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-na\u00efve or TNF\u03b1 inhibitor-experienced","volume":"7","author":"Ritchlin","year":"2021","journal-title":"RMD Open"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"Mosmann","year":"1986","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGF\u03b2 in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature04754","article-title":"Transforming growth factor-\u03b2 induces development of the TH17 lineage","volume":"441","author":"Mangan","year":"2006","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1086\/511051","article-title":"A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am J Hum Genet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000953020.05891.05","article-title":"Risankizumab induction therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized phase 3 INSPIRE study","volume":"118","author":"Edouard","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.immuni.2017.12.008","article-title":"Structural activation of pro-inflammatory human cytokine IL-23 by cognate IL-23 receptor enables recruitment of the shared receptor IL-12R\u03b21","volume":"48","author":"Bloch","year":"2018","journal-title":"Immunity"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S282466","article-title":"All are equal, some are more equal: targeting IL 12 and 23 in IBD - a clinical perspective","volume":"9","author":"Jefremow","year":"2020","journal-title":"Immunotargets Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab461","article-title":"Interleukin-23 in perspective","volume":"60","author":"Sherlock","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.11.009","article-title":"Interleukin-23-induced transcription factor blimp-1 promotes pathogenicity of T helper 17 cells","volume":"44","author":"Jain","year":"2016","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.immuni.2009.08.025","article-title":"Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis","volume":"31","author":"Lin","year":"2009","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J Exp Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13466","article-title":"IL-12 protects from psoriasiform skin inflammation","volume":"7","author":"Kulig","year":"2016","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.immuni.2019.06.008","article-title":"Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment","volume":"51","author":"Eftychi","year":"2019","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1908","article-title":"In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin","volume":"176","author":"Piskin","year":"2006","journal-title":"J Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J Exp Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140678","article-title":"CX\u2083CR1+ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22","volume":"211","author":"Longman","year":"2014","journal-title":"J Exp Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1471-1","article-title":"Locally renewing resident synovial macrophages provide a protective barrier for the joint","volume":"572","author":"Culemann","year":"2019","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.immuni.2018.07.007","article-title":"LAG3+ regulatory T cells restrain interleukin-23-producing CX3CR1+ gut-resident macrophages during Group 3 innate lymphoid cell-driven colitis","volume":"49","author":"Bauche","year":"2018","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2416","article-title":"Induction and molecular signature of pathogenic TH17 cells","volume":"13","author":"Lee","year":"2012","journal-title":"Nat Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1016\/j.cell.2021.11.018","article-title":"Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunity","volume":"184","author":"Schnell","year":"2021","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrd4176","article-title":"Therapeutic opportunities of the IL-22-IL-22R1 system","volume":"13","author":"Sabat","year":"2014","journal-title":"Nat Rev Drug Discovery"},{"key":"B57","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08769.x","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01549","article-title":"The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis","volume":"9","author":"Albanesi","year":"2018","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.05.008","article-title":"The current landscape of psoriasis genetics in 2020","volume":"99","author":"Ogawa","year":"2020","journal-title":"J Dermatol Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20963","article-title":"The biological basis of disease recurrence in psoriasis: a historical perspective and current models","volume":"186","author":"Puig","year":"2022","journal-title":"Br J Dermatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1782817","article-title":"Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1","volume":"33","author":"Griffiths","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Tha\u00e7i","year":"2021","journal-title":"Br J Dermatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study","volume":"139","author":"Gordon","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16426","article-title":"Efficacy and safety of continuous every 2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase 3 trial (IXORA-P)","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.05.046","article-title":"Humanized anti-IFN-\u03b3 (HuZAF) in the treatment of psoriasis","volume":"135","author":"Harden","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br J Dermatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614255","article-title":"Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis","volume":"12","author":"McGonagle","year":"2021","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab385","article-title":"Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints","volume":"60","author":"\u0141ukasik","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.147","article-title":"'MHC-I-opathy'-unified concept for spondyloarthritis and Beh\u00e7et disease","volume":"11","author":"McGonagle","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/art.24763","article-title":"HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats","volume":"60","author":"DeLay","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3263-4","article-title":"IL-23\/IL-17 axis in spondyloarthritis-bench to bedside","volume":"35","author":"Raychaudhuri","year":"2016","journal-title":"Clin Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","article-title":"The IL-23\/IL-17 axis in psoriatic arthritis","volume":"13","author":"Suzuki","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/art.40150","article-title":"Brief report: Group 3 innate lymphoid cells in human enthesis","volume":"69","author":"Cuthbert","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"\u00d6st\u00f6r","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B87","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2021-eular.479","article-title":"Guselkumab treatment modulates core psoriatic arthritis gene expression in two phase 3 clinical trials","volume":"80","author":"Siebert","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/art.41538","article-title":"Collagen turnover markers are associated with active psoriatic arthritis and decrease with guselkumab treatment in a phase-3 clinical trial [abstract]","volume":"72","author":"Schett","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B90","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jdv.14673","article-title":"Immune response patterns in non-communicable inflammatory skin diseases","volume":"32","author":"Eyerich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab119","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.623874","article-title":"IL-23 inhibition in ankylosing spondylitis: where did it go wrong","volume":"11","author":"Baeten","year":"2020","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0415-0","article-title":"Targeting immune cell circuits and trafficking in inflammatory bowel disease","volume":"20","author":"Neurath","year":"2019","journal-title":"Nat Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.02.072","article-title":"From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation","volume":"126","author":"Sands","year":"2004","journal-title":"Gastroenterology"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13607","article-title":"IL-23R mutation is associated with ulcerative colitis: a systemic review and meta-analysis","volume":"8","author":"Peng","year":"2017","journal-title":"Oncotarget"},{"key":"B101","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cgh.2020.09.028","article-title":"Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn's disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab093","article-title":"Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: results from the phase 2 open-label extension study","volume":"15","author":"Ferrante","year":"2021","journal-title":"J Crohn's colitis"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"Gastroenterology"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.1394","article-title":"Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial","volume":"155","author":"Terui","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B109","doi-asserted-by":"publisher","first-page":"iv4","DOI":"10.1093\/rheumatology\/keab266","article-title":"IL-23 orchestrating immune cell activation in arthritis","volume":"60","author":"Najm","year":"2021","journal-title":"Rheumatology"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510384496","article-title":"A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis","volume":"17","author":"Vollmer","year":"2011","journal-title":"Mult Scler"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3579","article-title":"Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease","volume":"18","author":"Pfeifle","year":"2017","journal-title":"Nat Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.9.3.319","article-title":"Why did IL-12\/IL-23 antibody therapy fail in multiple sclerosis","volume":"9","author":"Longbrake","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab022","article-title":"A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes","volume":"2","author":"Marwaha","year":"2021","journal-title":"Immunother Adv"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049595","article-title":"Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol","volume":"11","author":"Gregory","year":"2021","journal-title":"BMJ Open"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13298","article-title":"Distinct gene expression pathways in islets from individuals with short- and long-duration type 1 diabetes","volume":"20","author":"Mastracci","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.2337\/diabetes.49.12.1998","article-title":"Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice","volume":"49","author":"Fujihira","year":"2000","journal-title":"Diabetes"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.04.004","article-title":"Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial","volume":"48","author":"Conway","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"B118","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.jid.2021.02.725","article-title":"Pityriasis rubra pilaris treated with guselkumab: interim analysis of a single-arm trial","volume":"141","author":"Cutler","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.01019","article-title":"Transcytosis to cross the blood brain barrier, new advancements and challenges","volume":"12","author":"Pulgar","year":"2019","journal-title":"Front Neurosci"},{"key":"B121","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study","volume":"263","author":"Havrdova","year":"2016","journal-title":"J Neurol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24200","article-title":"Ustekinumab for the treatment of giant cell arteritis","volume":"73","author":"Matza","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.699848","article-title":"Depression and obesity in patients with psoriasis and psoriatic arthritis: is IL-17-mediated immune dysregulation the connecting link","volume":"12","author":"Zafiriou","year":"2021","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.114.006516","article-title":"Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23\/interleukin 17 axis","volume":"46","author":"Abbas","year":"2015","journal-title":"Stroke"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1999","article-title":"Pivotal role of cerebral interleukin-17-producing \u03b3\u03b4T cells in the delayed phase of ischemic brain injury","volume":"15","author":"Shichita","year":"2009","journal-title":"Nat Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.639353","article-title":"Microglia-derived interleukin 23: a crucial cytokine in Alzheimer's disease","volume":"12","author":"Nitsch","year":"2021","journal-title":"Front Neurol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000646","article-title":"IL-23 signaling regulation of pro-inflammatory T-cell migration uncovered by phosphoproteomics","volume":"18","author":"Alvarez-Salamero","year":"2020","journal-title":"PloS Biol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.905239","article-title":"Comparative analysis of single-cell transcriptome data reveals a novel role of keratinocyte-derived IL-23 in psoriasis","volume":"13","author":"Park","year":"2022","journal-title":"Front Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1250504","article-title":"Multi-omics segregate different transcriptomic impacts of anti-IL-17A blockade on type 17 T-cells and regulatory immune cells in psoriasis skin","volume":"14","author":"Kim","year":"2023","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3390\/vaccines10111977","article-title":"Allelic variants of HLA-C upstream region, PSORS1C3, MICA, TNFA and genes involved in epidermal homeostasis and barrier function influence the clinical response to anti-IL-12\/IL-23 treatment of patients with psoriasis","volume":"10","author":"Morelli","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B132","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.3390\/ijms24054568","article-title":"Compositional alteration of gut microbiota in psoriasis treated with IL-23 and IL-17 inhibitors","volume":"24","author":"Huang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300626","article-title":"IL-23 receptor expression on \u03b3\u03b4 T cells correlates with their enhancing or suppressive effects on autoreactive T cells in experimental autoimmune uveitis","volume":"191","author":"Liang","year":"2013","journal-title":"J Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20090","article-title":"Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways","volume":"185","author":"Tollenaere","year":"2021","journal-title":"Br J Dermatol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092044","article-title":"Decoding IL-23 signaling cascade for new therapeutic opportunities","volume":"9","author":"Pastor-Fernandez","year":"2020","journal-title":"Cells"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2017.157","article-title":"The human skin microbiome","volume":"16","author":"Byrd","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049822","article-title":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)","volume":"11","author":"Eyerich","year":"2021","journal-title":"BMJ Open"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1964420","article-title":"A non-clinical comparative study of IL-23 antibodies in psoriasis","volume":"13","author":"Zhou","year":"2021","journal-title":"MAbs"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214944","article-title":"Identification of myeloid cells in the human enthesis as the main source of local IL-23 production","volume":"78","author":"Bridgewood","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00540.2013","article-title":"Specific targeting of the IL-23 receptor, using a novel small peptide noncompetitive antagonist, decreases the inflammatory response","volume":"307","author":"Quiniou","year":"2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000592540.43886.35","article-title":"Safety, tolerability, and pharmacokinetics of PTG-200, an oral GI-restricted peptide antagonist of IL-23 receptor, in normal healthy volunteers","volume":"114","author":"Cheng","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"S190","DOI":"10.1016\/j.jid.2023.03.1121","article-title":"First-in-class oral peptide systemically targeting the IL-23 pathway","volume":"143","author":"Fourie","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B143","article-title":"In silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in Inflammatory Bowel Disease","volume-title":"J Crohns Colitis.","author":"Perrigoue","year":"2022"},{"key":"B144","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjab232.035","article-title":"Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study","volume-title":"J Crohns Colitis","author":"Sands","year":"2022"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1136\/annrheumdis-2023-eular.2982","article-title":"Differential and combinatorial mechanism of action of Golimumab and Guselkumab in ulcerative colitis induction therapy: IL-23 blackade drives restoration of normal epithelium and mucosal healing","volume":"82","author":"Desai","year":"2023","journal-title":"EULAR"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1331217\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T04:20:24Z","timestamp":1713154824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1331217\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":145,"alternative-id":["10.3389\/fimmu.2024.1331217"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1331217","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"article-number":"1331217"}}